Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic ultrasound activates pure prekallikrein.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2012
Same author

Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2012
Same author

Bilirubin and microangiopathy.

Ophthalmology·2012
Same author

The ultrasound frequency determines the degree of intrinsic coagulation activation.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2012
Same author

Lamotrigine triggers the contact phase of coagulation.

Epileptic disorders : international epilepsy journal with videotape·2012
Same author

Contact activation of coagulation depends on the maximal lipophilic trigger concentration.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2012

Related Experiment Video

Updated: May 29, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Inhibition of intrinsic thrombin generation.

Thomas W Stief1

  • 1Department of Clinical Chemistry, University Hospital Giessen & Marburg, Germany.

Drug Target Insights
|September 9, 2011
PubMed
Summary

This study measured the inhibitory concentrations (IC50) of anticoagulants like heparin and aprotinin on intrinsic thrombin generation using the INCA assay. Results show varying efficiencies, emphasizing the need for personalized anticoagulant monitoring.

Keywords:
INCALMW-heparinaprotininargininedalteparinheparinthrombin

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model
06:16

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model

Published on: April 19, 2024

Related Experiment Videos

Last Updated: May 29, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model
06:16

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model

Published on: April 19, 2024

Area of Science:

  • Coagulation science
  • Biochemistry
  • Pharmacology

Background:

  • The contact phase of coagulation is crucial in hemostasis and can be pathologically activated by cell fragments.
  • Several anticoagulants are clinically used to inhibit intrinsic thrombin generation.
  • Assessing anticoagulant efficacy is vital for patient safety and treatment effectiveness.

Purpose of the Study:

  • To determine the inhibitory concentrations 50% (IC50) of various anticoagulants on intrinsic thrombin generation.
  • To compare the efficacy of low molecular weight heparin (dalteparin), unfractionated heparin, aprotinin, and arginine.
  • To highlight the importance of individualized assessment of anticoagulant efficiency.

Main Methods:

  • Utilized the highly specific thrombin generation assay (INCA) for precise measurement.
  • Tested unfrozen pooled normal citrated plasma with varying concentrations of anticoagulants.
  • Employed chromogenic detection to quantify thrombin generation after incubation and inhibition.

Main Results:

  • The approximate IC50 values were determined as 0.01 IU/ml for dalteparin, 0.02 IU/ml for unfractionated heparin, 25 KIU/ml for aprotinin, and 12 mM for arginine.
  • Demonstrated differential inhibitory effects of the tested anticoagulants on intrinsic thrombin generation.
  • Established the reliability of the INCA assay with intra-assay coefficients of variation < 5%.

Conclusions:

  • The study provides quantitative data on the IC50 of common anticoagulants.
  • Individualized measurement of anticoagulant efficiency is recommended for optimal patient management.
  • The findings underscore the necessity of personalized medicine in anticoagulant therapy.